Nanogen (NGEN) Reports Q2 Loss of $0.07
More News related to NGEN
- Nanogen (NGEN) Reports a Q3 Loss; FY Guidance Unchanged
- Nanogen (NGEN) and The Elitech Group Announce Merger Agreement
- Nanogen (NGEN) Reports Q2 Loss of $0.07
- Nanogen (NGEN) Awarded New CDC Contract to Develop Molecular Diagnostic Test for Influenza and Avian Flu
- Nanogen (NGEN) Announces Consolidation of Point of Care Manufacturing Operations
More News related to Earnings
- Kinross Gold (KGC) Receives Authorization to Re-Commence Exploration on Project in Ecuador
- Sanofi-aventis (SNY) and Regeneron Pharmaceuticals (REGN) to Expand Global Collaboration
- Stryker (SYK) Announces Two Acquisitions
- Adobe (ADBE) Cutting 680 Full-Time Jobs to Align Costs with '10 Operating Plan
- Teva Pharma (TEVA) Gets Final U.S. FDA Approval for Generic Prevacid
Nanogen, Inc. (Nasdaq: NGEN) reports a Q2 loss of $0.07, compared to a $0.20 loss in the same quarter last year. Revenues for the quarter were $12.9 million, versus $10.7 million in Q207.
Nanogen, Inc., a diagnostics company, engages in developing, manufacturing, and selling diagnostic products for use in the in vitro diagnostic market in the United States, Canada, and Europe.
Related Categories
EarningsStocks Mentioned
-0.01Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
